Staar Surgical Co.
- STAA · Nasdaq
- Ophthalmic Goods
- Monrovia, CA
- 957 employees
- CIK 0000718937
Updated from SEC filings through
Top things to know
Executives
-
Warren Foust President and CEO 4, 2026-08-18 -
Deborah Andrews Executive Vice President and Chief Financial Officer 8-K, 2026-11-04 - Deborah J. Andrews Chief Financial Officer & EVP 4, 2026-08-18
-
David Bailey Chief Commercial Officer 8-K, 2026-09-10 -
Magda Michna Chief Development Officer 4, 2026-08-18 - Nathaniel Sisitsky Chief Legal Officer 4, 2025-12-12
What leadership is saying
“Our record nine-month performance keeps us firmly on track to deliver strong full-year GAAP net income with free cash flow and a debt-free balance sheet”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
Staar Surgical Co is a U.S. public company in ophthalmic goods (SIC 3851), headquartered in Monrovia, CA. It trades as STAA on Nasdaq. Revenue was $239M in the fiscal year ending January 2, 2026, -23.7% from the year before. It reported about 957 employees. Warren Foust is President and CEO.
Five-year financials
| Metric | FY2026 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $239M 10-K, 2026-03-03 | $314M 10-K, 2026-03-03 | $322M 10-K, 2026-03-03 | $239M 10-K, 2026-03-03 | $230M 10-K, 2024-02-27 |
| Operating income | -$91.7M 10-K, 2026-03-03 | -$12.6M 10-K, 2026-03-03 | $28.1M 10-K, 2026-03-03 | $43.8M 10-K, 2025-02-21 | $33.3M 10-K, 2024-02-27 |
| SG&A | $274M 10-K, 2026-03-03 | $252M 10-K, 2026-03-03 | $225M 10-K, 2026-03-03 | $180M 10-K, 2025-02-21 | $145M 10-K, 2024-02-27 |
| Net income | -$80.4M 10-K, 2026-03-03 | -$20.2M 10-K, 2026-03-03 | $21.3M 10-K, 2026-03-03 | $39.7M 10-K, 2025-02-21 | $27.5M 10-K, 2024-02-27 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Warren Foust President and Chief Executive Officer at STAAR Surgical | Global MedTech Executive | Advancing Lens-Based Refractive Surgery | Driving Revenue Growth, Margin Ex | President and CEO | 4, 2026-08-18 |
| Stephen C. Farrell | Named in proxy bio: CEO | DEF 14A, 2026-05-04 |
| Deborah Andrews Executive Vice President, Chief Financial Officer at STAAR Surgical | Executive Vice President and Chief Financial Officer | 8-K, 2026-11-04 |
| Deborah J. Andrews | Chief Financial Officer & EVP | 4, 2026-08-18 |
| David Bailey | Chief Commercial Officer | 8-K, 2026-09-10 |
| Magda Michna Chief Development Officer, Medical Devices, Ophthalmology | Chief Development Officer | 4, 2026-08-18 |
| Nathaniel Sisitsky | Chief Legal Officer | 4, 2025-12-12 |
| Arthur C. Butcher | Board member (per proxy) bio: director | DEF 14A, 2026-05-04 |
| Christopher M. Wang | Board member (per proxy) bio: director | DEF 14A, 2026-05-04 |
| Lilian Y. Zhou | Board member (per proxy) bio: director | DEF 14A, 2026-05-04 |
| Christopher Min Fang Wang | Director | 10-K, 2026-03-03 |
| Lilian Zhou | Director | 10-K, 2026-03-03 |
| Louis E. Silverman | Director | 10-K, 2026-03-03 |
| Neal C. Bradsher | Director | 10-K, 2026-03-03 |
| Richard T. LeBuhn | Director | 10-K, 2026-03-03 |
| Wei Jiang | Director | 10-K, 2026-03-03 |
What Staar Surgical Co does
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or “refractive” surgery. We have been dedicated solely to ophthalmic surgery for over 40 years.
Shares and governance
| Shares outstanding | 50.2 million (as of October 30, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $884M (as of June 27, 2025) | 10-K, March 3, 2026 |
| Reportable segments | 1 (period ending October 2, 2026) | 10-Q, November 4, 2026 |
| Latest proxy statement | Meeting May 1, 2026 (filed May 4, 2026) | DEF 14A, May 4, 2026 |
| Auditor | Bdo Usa, P.c. (Los Angeles, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| March 13, 2026 | Partners L.P. Broadwood Director | Buy | 670,213 | $12.3M | Form 4, March 13, 2026 |
| March 13, 2026 | Neal C. Bradsher Director | Buy | 670,213 | $12.3M | Form 4, March 13, 2026 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-10
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-12
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-06
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-22
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-06-09
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-13
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-08
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-03
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-05
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Staar Surgical Co
- What does Staar Surgical Co do?
- In its own words, from Item 1 of its 10-K: "STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or “refractive” surgery. We have been dedicated solely to ophthalmic surgery for over 40 years."
- What is Staar Surgical Co's revenue?
- $239M for the fiscal year ending January 2, 2026, from its 10-K filed March 3, 2026.
- Is Staar Surgical Co profitable?
- Staar Surgical Co reported net income of -$80.4M for the fiscal year ending January 2, 2026.
- How many employees does Staar Surgical Co have?
- About 957 as of January 2, 2026, as stated in its annual report.
- Who is the CEO of Staar Surgical Co?
- Warren Foust, President and CEO, as named in a 4 filed August 18, 2026.
- Who is the CFO of Staar Surgical Co?
- Deborah Andrews, Executive Vice President and Chief Financial Officer, as named in a 8-K filed November 4, 2026.
- Where is Staar Surgical Co headquartered?
- Monrovia, CA.
- What is Staar Surgical Co's stock ticker?
- STAA on Nasdaq.
- What industry is Staar Surgical Co in?
- Ophthalmic Goods, SIC code 3851.
- What is Staar Surgical Co's website?
- staar.com.
- When does Staar Surgical Co report earnings next?
- February 3, 2027. Source: estimate_8k_pattern.
- Is Staar Surgical Co a public company?
- Yes. Staar Surgical Co files with the SEC under CIK 0000718937 and trades as STAA.
- Who audits Staar Surgical Co?
- Bdo Usa, P.c., Los Angeles, California, as named in its latest annual report (10-K).
- How many shares of Staar Surgical Co are outstanding?
- 50.2 million shares as of October 30, 2026, from its 10-Q filed November 4, 2026.
- What is Staar Surgical Co's public float?
- $884M as of June 27, 2025, as reported on the cover of its 10-K filed March 3, 2026.
- How many business segments does Staar Surgical Co report?
- 1 reportable segment for the period ending October 2, 2026, from its 10-Q filed November 4, 2026.
- When is Staar Surgical Co's annual shareholder meeting?
- May 1, 2026, per its proxy statement (DEF 14A) filed May 4, 2026.
- Have Staar Surgical Co insiders traded stock recently?
- Since March 13, 2026, officers and directors reported 0 open-market sales and 2 purchases worth about $24.5M on Forms 4 and 5. The most recent: Partners L.P. Broadwood (Director) bought 670,213 shares on March 13, 2026.